Review: Towards molecular imaging of multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 262-272

  Owen, David R J ^a   Piccini, Paola ^b   Matthews, Paul M ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

molecular imaging; multiple sclerosis; positron emission tomography

Indexed keywords

BENZODIAZEPINE RECEPTOR; CANNABINOID RECEPTOR; CARBON 11; CARRIER PROTEIN; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; MYELIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEUROTRANSMITTER; QUINOLINE DERIVATIVE; RADIOLIGAND; TRACER; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BRAIN METABOLISM; CELL FUNCTION; CHOLINERGIC SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REMYELINIZATION; REVIEW; BRAIN; HOSPITALIZATION; METABOLISM; METHODOLOGY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 79953205244     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510390070     Document Type: Review

References (87)

1. Miller DH, Filippi M., Fazekas F., Frederiksen JL, Matthews PM, Montalban X., et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 2004 ; 56: 273-278. (Pubitemid 39037922)
2. Barkhof F., Calabresi PA, Miller DH and Reingold SC Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009 ; 5: 256-266.
3. Arnold DL and Matthews PM MRI in the diagnosis and management of multiple sclerosis. Neurology 2002 ; 58 (Suppl 4). S23 - S31.
4. Guo Q., Brady M. and Gunn RN A biomathematical modeling approach to central nervous system radioligand discovery and development. J Nucl Med 2009 ; 50: 1715-1723.
5. Thie JA Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004 ; 45: 1431-1434. (Pubitemid 47618494)
6. Turkheimer FE, Edison P., Pavese N., Roncaroli F., Anderson AN, Hammers A., et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 2007 ; 48: 158-167. (Pubitemid 47555390)
7. Venneti S., Lopresti BJ and Wiley CA The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006 ; 80: 308-322. (Pubitemid 46107737)
8. Kreutzberg GW Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996 ; 19: 312-318. (Pubitemid 26349059)
9. Gehrmann J., Matsumoto Y. and Kreutzberg GW Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995 ; 20: 269-287.
10. Benveniste EN Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 1997 ; 75: 165-173. (Pubitemid 27132679)
11. Ransohoff RM and Perry VH Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009 ; 27: 119-145.
12. Bruck W., Porada P., Poser S., Rieckmann P., Hanefeld F., Kretzschmar HA, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995 ; 38: 788-796.
13. Lacapere JJ and Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 2003 ; 68: 569-585. (Pubitemid 37075920)
14. Doble A., Malgouris C., Daniel M., Daniel N., Imbault F., Basbaum A., et al. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull 1987 ; 18: 49-61. (Pubitemid 17017497)
15. Papadopoulos V., Baraldi M., Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P., et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006 ; 27: 402-409. (Pubitemid 44069585)
16. Maeda J., Higuchi M., Inaji M., Ji B., Haneda E., Okauchi T., et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007 ; 1157: 100-111. (Pubitemid 46935074)
17. Ji B., Maeda J., Sawada M., Ono M., Okauchi T., Inaji M., et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 2008 ; 28: 12255-12267.
18. Shah F., Hume SP, Pike VW, Ashworth S. and McDermott J. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol 1994 ; 21: 573-581. (Pubitemid 24173248)
19. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006 ; 21: 404-412. (Pubitemid 43099863)
20. Ramsay SC, Weiller C., Myers R., Cremer JE, Luthra SK, Lammertsma AA, et al. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 1992 ; 339: 1054-1055.
21. Cagnin A., Myers R., Gunn RN, Lawrence AD, Stevens T., Kreutzberg GW, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001 ; 124: 2014-2027. (Pubitemid 32945901)
22. Edison P., Archer HA, Gerhard A., Hinz R., Pavese N., Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008 ; 32: 412-419.
23. Banati RB, Newcombe J., Gunn RN, Cagnin A., Turkheimer F., Heppner F., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000 ; 123: 2321-2337.
24. Chen MK, Baidoo K., Verina T. and Guilarte TR Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 2004 ; 127: 1379-1392. (Pubitemid 38745516)
25. Debruyne JC, Versijpt J., Van Laere KJ, De VF, Keppens J., Strijckmans K., et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003 ; 10: 257-264. (Pubitemid 36609480)
26. Versijpt J., Debruyne JC, Van Laere KJ, De VF, Keppens J., Strijckmans K., et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 2005 ; 11: 127-134. (Pubitemid 40403248)
27. Rao SM, Leo GJ, Bernardin L. and Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991 ; 41: 685-691.
28. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002 ; 15: 239-245. (Pubitemid 34596884)
29. Cifelli A., Arridge M., Jezzard P., Esiri MM, Palace J. and Matthews PM Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002 ; 52: 650-653. (Pubitemid 35246871)
30. Bo L., Vedeler CA, Nyland HI, Trapp BD and Mork SJ Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003 ; 62: 723-732. (Pubitemid 36870458)
31. Kutzelnigg A., Lucchinetti CF, Stadelmann C., Bruck W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 ; 128: 2705-2712. (Pubitemid 41552953)
32. Calabrese M., Rocca MA, Atzori M., Mattisi I., Favaretto A., Perini P., et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol 2010 ; 67: 376-383.
33. Bagnato F., Salman Z., Kane R., Auh S., Cantor FK, Ehrmantraut M., et al. T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult Scler 2010 ; 16: 1203-1212.
34. Mainero C., Benner T., Radding A., van der KA, Jensen R., Rosen BR, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009 ; 73: 941-948.
35. Bagnato F., Yao B., Cantor F., Merkle H., Condon E., Montequin M., et al. Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: observations from a post-mortem 3 Tesla imaging study. J Neurol Sci 2009 ; 282: 80-85.
36. Schmierer K., Parkes HG, So PW, An SF, Brandner S., Ordidge RJ, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain 2010 ; 133: 858-867.
37. Vercellino M., Merola A., Piacentino C., Votta B., Capello E., Mancardi GL, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007 ; 66: 732-739. (Pubitemid 47344252)
38. Politis M., Giannetti P., Su P., Turkheimer F., Keihaninejad S., Wu K., et al. Cortical microglial activation is associated with disability in secondary progressive multiple sclerosis: An in vivo imaging study. Neurology 2010 ; 74 (Suppl 2): A290.
39. Chauveau F., Boutin H., Van CN, Dolle F. and Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008 ; 35: 2304-2319.
40. Fujimura Y., Zoghbi SS, Simeon FG, Taku A., Pike VW, Innis RB, et al. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06. J Nucl Med 2009 ; 50: 1047-1053.
41. Wilson AA, Garcia A., Parkes J., McCormick P., Stephenson KA, Houle S., et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol 2008 ; 35: 305-314. (Pubitemid 351381972)
42. Ikoma Y., Yasuno F., Ito H., Suhara T., Ota M., Toyama H., et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J Cereb Blood Flow Metab 2007 ; 27: 173-184. (Pubitemid 46006595)
43. Endres CJ, Pomper MG, James M., Uzuner O., Hammoud DA, Watkins CC, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009 ; 50: 1276-1282.
44. Fookes CJ, Pham TQ, Mattner F., Greguric I., Loc'h C., Liu X., et al. Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem 2008 ; 51: 3700-3712. (Pubitemid 351956502)
45. Van Camp N., Boisgard R., Kuhnast B., Theze B., Viel T., Gregoire MC, et al. In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C]CLINME and [(11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging 2010 ; 37: 962-972.
46. Imaizumi M., Briard E., Zoghbi SS, Gourley JP, Hong J., Fujimura Y., et al. Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 2008 ; 39: 1289-1298.
47. Fujita M., Imaizumi M., Zoghbi SS, Fujimura Y., Farris AG, Suhara T., et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008 ; 40: 43-52.
48. Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I., Bergstrom M., et al. Two binding sites for [(3)H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010 ; 30: 1608-1608.
49. David RJ Owen, Roger N Gunn, Eugenii A Rabiner, Idriss Bennacef, Masahiro Fujita, William C Kreisl, et al. Mixed Affinity Binding in Humans with 18 kDa Translocator Protein (TSPO) Ligands. J Nucl Med 2010. [In Press].
50. Kreisl WC, Fujita M., Fujimura Y., Kimura N., Jenko KJ, Kannan P., et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010 ; 49: 2924-2932.
51. Dousset V., Brochet B., Deloire MS, Lagoarde L., Barroso B., Caille JM, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006 ; 27: 1000-1005. (Pubitemid 44897675)
52. Bendszus M. and Stoll G. Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003 ; 23: 10892-10896. (Pubitemid 37499698)
53. Kleinschnitz C., Bendszus M., Frank M., Solymosi L., Toyka KV and Stoll G. In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab 2003 ; 23: 1356-1361. (Pubitemid 37409799)
54. Cabral GA and Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009 ; 11: e3.
55. Herkenham M., Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990 ; 87: 1932-1936.
56. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 ; 232: 54-61.
57. Carlisle SJ, Marciano-Cabral F., Staab A., Ludwick C. and Cabral GA Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002 ; 2: 69-82. (Pubitemid 33086805)
58. Maresz K., Carrier EJ, Ponomarev ED, Hillard CJ and Dittel BN Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005 ; 95: 437-445. (Pubitemid 41457512)
59. Benito C., Romero JP, Tolon RM, Clemente D., Docagne F., Hillard CJ, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007 ; 27: 2396-2402. (Pubitemid 46340977)
60. Evens N., Muccioli GG, Houbrechts N., Lambert DM, Verbruggen AM, Van LK, et al. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl Med Biol 2009 ; 36: 455-465.
61. Horti AG, Gao Y., Ravert HT, Finley P., Valentine H., Wong DF, et al. Synthesis and biodistribution of [(11)C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB(2)). Bioorg Med Chem 2010 ; 18: 5202-5207.
62. Dubois-Dalcq M., Williams A., Stadelmann C., Stankoff B., Zalc B. and Lubetzki C. From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases. Brain 2008 ; 131: 1686-1700. (Pubitemid 351957449)
63. Henkelman RM, Stanisz GJ and Graham SJ Magnetization transfer in MRI: a review. NMR Biomed 2001 ; 14: 57-64. (Pubitemid 32401348)
64. Schmierer K., Wheeler-Kingshott CA, Boulby PA, Scaravilli F., Altmann DR, Barker GJ, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 2007 ; 35: 467-477. (Pubitemid 46400551)
65. Laule C., Vavasour IM, Kolind SH, Li DK, Traboulsee TL, Moore GR, et al. Magnetic resonance imaging of myelin. Neurotherapeutics 2007 ; 4: 460-484. (Pubitemid 46962414)
66. Stankoff B., Wang Y., Bottlaender M., Aigrot MS, Dolle F., Wu C., et al. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A 2006 ; 103: 9304-9309. (Pubitemid 43902573)
67. Wang Y., Wu C., Caprariello AV, Somoza E., Zhu W., Wang C., et al. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci 2009 ; 29: 14663-14669.
68. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res 1999 ; 24: 321-329. (Pubitemid 29067977)
69. Schiepers C., Van HP, Vandenberghe R., Van OS, Dupont P., Demaerel P., et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 1997 ; 3: 8-17. (Pubitemid 27234858)
70. Radu CG, Shu CJ, Nair-Gill E., Shelly SM, Barrio JR, Satyamurthy N., et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med 2008 ; 14: 783-788. (Pubitemid 351951515)
71. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1981 ; 1: 7-36. (Pubitemid 11026196)
72. Bakshi R., Miletich RS, Kinkel PR, Emmet ML and Kinkel WR High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998 ; 8: 228-234. (Pubitemid 28457989)
73. Roelcke U., Kappos L., Lechner-Scott J., Brunnschweiler H., Huber S., Ammann W., et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997 ; 48: 1566-1571.
74. Blinkenberg M., Rune K., Jensen CV, Ravnborg M., Kyllingsbaek S., Holm S., et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000 ; 54: 558-564. (Pubitemid 30082918)
75. Blinkenberg M., Jensen CV, Holm S., Paulson OB and Sorensen PS A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 1999 ; 53: 149-153. (Pubitemid 29329663)
76. Paulesu E., Perani D., Fazio F., Comi G., Pozzilli C., Martinelli V., et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage 1996 ; 4: 87-96. (Pubitemid 26337401)
77. Heiss WD, Grond M., Thiel A., Ghaemi M., Sobesky J., Rudolf J., et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke 1998 ; 29: 454-461. (Pubitemid 28086691)
78. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A. and Leigh PN Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000 ; 123: 2289-2296.
79. Ohyama M., Senda M., Ishiwata K., Kitamura S., Mishina M., Ishii K., et al. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999 ; 13: 309-315.
80. Murai H., Kiyosawa M., Suzuki Y., Mizoguchi S., Ishii K., Ishikawa K., et al. A case of multiple sclerosis with homonymous hemianopia examined by positron emission tomography. Jpn J Ophthalmol 2004 ; 48: 591-593. (Pubitemid 40104629)
81. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 ; 1: CD005593.
82. Greene YM, Tariot PN, Wishart H., Cox C., Holt CJ, Schwid S., et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000 ; 20: 350-356. (Pubitemid 30318365)
83. Krupp LB, Christodoulou C., Melville P., Scherl WF, MacAllister WS and Elkins LE Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004 ; 63: 1579-1585. (Pubitemid 39507572)
84. Volkow ND, Ding YS, Fowler JS and Gatley SJ Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 2001 ; 49: 211-220. (Pubitemid 32178430)
85. Sosnovik DE and Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol 2007 ; 18: 4-10. (Pubitemid 46227964)
86. Wong DF, Tauscher J. and Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009 ; 34: 187-203.
87. Bomanji JB, Costa DC and Ell PJ Clinical role of positron emission tomography in oncology. Lancet Oncol 2001 ; 2: 157-164. (Pubitemid 33585927)